Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAI NASDAQ:CNTB NASDAQ:GNLX NASDAQ:IFRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.14+2.7%$1.15$1.01▼$8.08$34.27M0.3668,358 shs488,737 shsCNTBConnect Biopharma$2.12+1.0%$2.50$0.85▼$3.82$132.22M-0.22221,690 shs173,605 shsGNLXGenelux$2.96+2.8%$2.80$2.29▼$8.53$129.14M0.56139,022 shs116,792 shsIFRXInflaRx$1.60-4.8%$1.88$0.74▼$2.95$121.45M2.421.13 million shs773,735 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics+1.83%-10.12%-6.72%-25.50%-37.99%CNTBConnect Biopharma+0.96%-8.70%-21.64%-21.93%+156.41%GNLXGenelux+0.70%-6.49%-3.03%+10.77%+8.68%IFRXInflaRx+3.70%-16.00%-30.86%+77.59%+101.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.14+2.7%$1.15$1.01▼$8.08$34.27M0.3668,358 shs488,737 shsCNTBConnect Biopharma$2.12+1.0%$2.50$0.85▼$3.82$132.22M-0.22221,690 shs173,605 shsGNLXGenelux$2.96+2.8%$2.80$2.29▼$8.53$129.14M0.56139,022 shs116,792 shsIFRXInflaRx$1.60-4.8%$1.88$0.74▼$2.95$121.45M2.421.13 million shs773,735 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics+1.83%-10.12%-6.72%-25.50%-37.99%CNTBConnect Biopharma+0.96%-8.70%-21.64%-21.93%+156.41%GNLXGenelux+0.70%-6.49%-3.03%+10.77%+8.68%IFRXInflaRx+3.70%-16.00%-30.86%+77.59%+101.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.25Hold$11.00864.91% UpsideCNTBConnect Biopharma 2.86Moderate Buy$7.20239.62% UpsideGNLXGenelux 2.50Moderate Buy$18.00508.11% UpsideIFRXInflaRx 2.71Moderate Buy$7.00337.50% UpsideCurrent Analyst Ratings BreakdownLatest BTAI, CNTB, IFRX, and GNLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/13/2026IFRXInflaRx Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$7.00 ➝ $9.005/11/2026IFRXInflaRx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $8.005/11/2026IFRXInflaRx Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$2.00 ➝ $4.005/4/2026CNTBConnect Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/24/2026IFRXInflaRx OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.00 ➝ $5.004/21/2026GNLXGenelux Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026IFRXInflaRx GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$640K55.01N/AN/A($4.37) per share-0.26CNTBConnect Biopharma$60K2,224.59N/AN/A$0.75 per share2.83GNLXGenelux$10K13,272.64N/AN/A$0.30 per share9.87IFRXInflaRx$30K3,855.47N/AN/A$0.65 per share2.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$69.90M-$5.75N/AN/AN/A-11,078.53%N/A-201.53%8/11/2026 (Estimated)CNTBConnect Biopharma-$55.48M-$1.15N/AN/AN/AN/A-122.29%-97.07%8/12/2026 (Estimated)GNLXGenelux-$32.15M-$0.85N/AN/AN/AN/A-174.55%-123.65%8/6/2026 (Estimated)IFRXInflaRx-$51.63M-$0.71N/AN/AN/AN/A-88.30%-65.77%8/6/2026 (Estimated)Latest BTAI, CNTB, IFRX, and GNLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BTAIBioXcel Therapeutics-$0.5325-$0.54-$0.0075-$0.54$0.38 million$0.21 million5/12/2026Q1 2026CNTBConnect Biopharma-$0.29-$0.34-$0.05-$0.34N/A$0.02 million5/7/2026Q1 2026GNLXGenelux-$0.18-$0.20-$0.02-$0.20$0.01 millionN/A5/7/2026Q1 2026IFRXInflaRx-$0.17-$0.09+$0.08-$0.09$0.01 millionN/A3/31/2026Q4 2025CNTBConnect Biopharma-$0.30-$0.27+$0.03-$0.27$0.00 million($0.05) million3/27/2026Q4 2025BTAIBioXcel Therapeutics-$0.58-$0.58N/A$0.65$0.15 millionN/A3/27/2026Q4 2025GNLXGenelux-$0.22-$0.24-$0.02-$0.24N/A$0.01 million3/20/2026Q4 2025IFRXInflaRx-$0.17-$0.17N/A-$0.18$0.03 million($0.04) million3/19/2026Q4 2025GNLXGenelux-$0.22-$0.24-$0.02-$0.24N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A0.620.61CNTBConnect Biopharma0.013.233.23GNLXGeneluxN/A3.683.68IFRXInflaRxN/A4.164.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%CNTBConnect Biopharma58.72%GNLXGenelux37.33%IFRXInflaRx42.39%Insider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics3.70%CNTBConnect Biopharma22.60%GNLXGenelux7.50%IFRXInflaRx16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics9030.88 million29.74 millionNo DataCNTBConnect Biopharma11062.96 million48.73 millionOptionableGNLXGenelux1044.84 million41.48 millionNot OptionableIFRXInflaRx6072.29 million60.51 millionOptionableBTAI, CNTB, IFRX, and GNLX HeadlinesRecent News About These CompaniesWhat Do Analysts Say About InflaRx N.V. (IFRX)?June 10 at 3:11 PM | insidermonkey.comHere’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy NowMay 31, 2026 | insidermonkey.comRaymond James upgrades InflaRx NV (IFRX)May 14, 2026 | msn.comInflaRx NV (IFRX) price target decreased by 16.67% to 7.29May 14, 2026 | msn.comInflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical StudyMay 9, 2026 | theglobeandmail.comInflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases TranscriptMay 8, 2026 | seekingalpha.comInflaRx N.V. Completes $150 Million Underwritten Offering of Ordinary Shares to Advance Pipeline ActivitiesMay 8, 2026 | quiverquant.comQInflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary SharesMay 8, 2026 | globenewswire.comInflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026May 7, 2026 | tipranks.comInflaRx N.V. (IFRX) Regains Compliance With NasdaqMay 7, 2026 | finance.yahoo.comInflaRx prices $150M offering of ordinary sharesMay 6, 2026 | msn.comInflaRx Advances Development of Izicopan for ANCA-Associated Vasculitis and Broader Renal Diseases with Upcoming Capital Markets Day in Summer 2026May 6, 2026 | quiverquant.comQInflaRx Files Q1 2026 Financials with SEC via Form 6-KMay 6, 2026 | tipranks.comInflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary SharesMay 6, 2026 | globenewswire.comInflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal DiseasesMay 6, 2026 | globenewswire.comTop 5 Hot Penny Stocks to Buy NowMay 6, 2026 | insidermonkey.comAnalysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)May 5, 2026 | theglobeandmail.comInflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver MicrosomesMay 4, 2026 | globenewswire.comInfraRX Down Ahead of Next Quarterly ReportMay 1, 2026 | baystreet.caInflaRx N.V. to Publish Q1 2026 Financial Results on May 7, 2026May 1, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBTAI, CNTB, IFRX, and GNLX Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$1.14 +0.03 (+2.70%) Closing price 04:00 PM EasternExtended Trading$1.17 +0.03 (+2.63%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Connect Biopharma NASDAQ:CNTB$2.12 +0.02 (+0.95%) Closing price 04:00 PM EasternExtended Trading$2.12 0.00 (-0.24%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Genelux NASDAQ:GNLX$2.96 +0.08 (+2.78%) Closing price 04:00 PM EasternExtended Trading$2.96 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.InflaRx NASDAQ:IFRX$1.60 -0.08 (-4.76%) Closing price 04:00 PM EasternExtended Trading$1.60 +0.00 (+0.31%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
